DK1605939T3 - Farmaceutisk anvendelse af 1-azabicyklo-2.2.2 oktaner og en fremgangsmåde til at teste forbindelser for den egenskab at aktivere inaktive WT P53 - Google Patents
Farmaceutisk anvendelse af 1-azabicyklo-2.2.2 oktaner og en fremgangsmåde til at teste forbindelser for den egenskab at aktivere inaktive WT P53Info
- Publication number
- DK1605939T3 DK1605939T3 DK04723128T DK04723128T DK1605939T3 DK 1605939 T3 DK1605939 T3 DK 1605939T3 DK 04723128 T DK04723128 T DK 04723128T DK 04723128 T DK04723128 T DK 04723128T DK 1605939 T3 DK1605939 T3 DK 1605939T3
- Authority
- DK
- Denmark
- Prior art keywords
- octanes
- azabicyclo
- inactive
- property
- pharmaceutical use
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45652503P | 2003-03-24 | 2003-03-24 | |
SE0300812A SE0300812D0 (sv) | 2003-03-24 | 2003-03-24 | Use of chemical compounds for preparing pharmaceutical compositions, and method of testing substances for medical effect |
PCT/SE2004/000452 WO2004084893A1 (fr) | 2003-03-24 | 2004-03-24 | Utilisation pharmaceutique de 1-azabicyclo[2.2.2]octanes et procede d'essai de composes concernant la capacite d'activation de wt p53 inactif |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1605939T3 true DK1605939T3 (da) | 2009-03-09 |
Family
ID=33100505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04723128T DK1605939T3 (da) | 2003-03-24 | 2004-03-24 | Farmaceutisk anvendelse af 1-azabicyklo-2.2.2 oktaner og en fremgangsmåde til at teste forbindelser for den egenskab at aktivere inaktive WT P53 |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1605939B1 (fr) |
JP (1) | JP2006521375A (fr) |
AT (1) | ATE411020T1 (fr) |
AU (1) | AU2004224488B2 (fr) |
CA (1) | CA2519795A1 (fr) |
DE (1) | DE602004017146D1 (fr) |
DK (1) | DK1605939T3 (fr) |
ES (1) | ES2315650T3 (fr) |
NZ (1) | NZ542212A (fr) |
PL (1) | PL1605939T3 (fr) |
WO (1) | WO2004084893A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0400708D0 (sv) | 2004-03-22 | 2004-03-22 | Aprea Ab | New compounds and use thereof |
BR112012017994B8 (pt) | 2010-01-21 | 2020-12-08 | Aprea Ab | composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio |
CN104860994A (zh) * | 2014-02-20 | 2015-08-26 | 中国药科大学 | 3-奎宁环酮类含磷化合物的制备及其医药用途 |
CN109280054A (zh) * | 2017-07-21 | 2019-01-29 | 上海时莱生物技术有限公司 | 氘代3-奎宁环酮类化合物、制备方法及用途 |
CN109280056A (zh) * | 2017-07-21 | 2019-01-29 | 上海时莱生物技术有限公司 | 手性3-奎宁环酮类化合物、制备方法及用途 |
EP3853227A1 (fr) * | 2018-09-20 | 2021-07-28 | Aprea Therapeutics AB | Dérivés de quinuclidine-3-one et leur utilisation dans le traitement du cancer |
EP4031136A1 (fr) | 2019-09-18 | 2022-07-27 | Aprea Therapeutics AB | Traitement combiné contenant un réactivateur de p53 et un inhibiteur d'une protéine anti-apoptotique de la famille bcl-2 |
WO2021170772A1 (fr) | 2020-02-26 | 2021-09-02 | Aprea Therapeutics Ab | Traitement combiné contenant un réactivateur de p53 et un inhibiteur de signalisation à médiation de cd47 |
WO2021180338A1 (fr) | 2020-03-09 | 2021-09-16 | Aprea Therapeutics Ab | Polythérapie avec un réactivateur de p53 et un inhibiteur d'adn méthyltransférase post-greffe de cellules souches |
WO2022175402A1 (fr) | 2021-02-18 | 2022-08-25 | Aprea Therapeutics Ab | Dérivés de quinuclidine-3-one |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE413176T1 (de) * | 2000-09-20 | 2008-11-15 | Aprea Ab | Verwendung von 1-azabicyclo(2.2.2)octan-3-on- derivaten zur behandlung von krebstumoren |
ES2269975T3 (es) * | 2002-02-21 | 2007-04-01 | Aprea Ab | Uso de compuestos de bajo peso molecular para preparar un medicamento util para tratar enfermedades mediadas por p53 mutante. |
-
2004
- 2004-03-24 PL PL04723128T patent/PL1605939T3/pl unknown
- 2004-03-24 AU AU2004224488A patent/AU2004224488B2/en not_active Expired
- 2004-03-24 EP EP04723128A patent/EP1605939B1/fr not_active Expired - Lifetime
- 2004-03-24 ES ES04723128T patent/ES2315650T3/es not_active Expired - Lifetime
- 2004-03-24 JP JP2006507983A patent/JP2006521375A/ja active Pending
- 2004-03-24 AT AT04723128T patent/ATE411020T1/de active
- 2004-03-24 CA CA002519795A patent/CA2519795A1/fr not_active Abandoned
- 2004-03-24 WO PCT/SE2004/000452 patent/WO2004084893A1/fr active Application Filing
- 2004-03-24 NZ NZ542212A patent/NZ542212A/en unknown
- 2004-03-24 DK DK04723128T patent/DK1605939T3/da active
- 2004-03-24 DE DE602004017146T patent/DE602004017146D1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP1605939A1 (fr) | 2005-12-21 |
JP2006521375A (ja) | 2006-09-21 |
NZ542212A (en) | 2008-04-30 |
ATE411020T1 (de) | 2008-10-15 |
AU2004224488A1 (en) | 2004-10-07 |
PL1605939T3 (pl) | 2009-04-30 |
DE602004017146D1 (de) | 2008-11-27 |
WO2004084893A1 (fr) | 2004-10-07 |
EP1605939B1 (fr) | 2008-10-15 |
AU2004224488B2 (en) | 2009-09-10 |
CA2519795A1 (fr) | 2004-10-07 |
ES2315650T3 (es) | 2009-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE269846T1 (de) | N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen | |
ATE334985T1 (de) | Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe | |
TR200103186T2 (tr) | MEK enzimlerinin inhibitörleri olarak kinolin türevleri | |
NO20044731L (no) | Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere | |
EA200100972A1 (ru) | Новые соединения и композиции как ингибиторы протеаз | |
NO20025601D0 (no) | Arylmetylaminderivater for anvendelse som tryptaseinhibitorer | |
DE60133555D1 (de) | Verbindungen und gemische zur verabreichung eines aktiven agens | |
BR0013200A (pt) | Compostos derivados de heterobiciclos contendo nitrogênio, composições farmacêuticas, método de tratamento ou prevenção de uma disfunção tromboembólica e uso dos compostos | |
HUP0401740A2 (hu) | N-szubsztituált hidroxipirimidinon-karboxamid HIV-integráz inhibitorok és ezeket tartalmazó gyógyszerkészítmények | |
NO20064347L (no) | Substituerte 1,2,3,4-tetrahydroisokinolinderivater | |
ATE496620T1 (de) | 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren | |
ATE300541T1 (de) | Pyrazolopyridinderivate | |
ATE370139T1 (de) | Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs | |
DE60204452D1 (de) | Pyrazolo[1,5]pyridinderivate | |
ATE470443T1 (de) | Indol-1-yl-essigsäurederivate | |
NO20056192L (no) | Kapaseinhibitorer og anvendelse derav | |
DK1605939T3 (da) | Farmaceutisk anvendelse af 1-azabicyklo-2.2.2 oktaner og en fremgangsmåde til at teste forbindelser for den egenskab at aktivere inaktive WT P53 | |
EE05091B1 (et) | Oligosahhariidid, nende valmistamismeetod ja kasutamine ning farmatseutilised kompositsioonid | |
NO20061033L (no) | Sammensetninger og fremgangsmater for levering av biologiske aktive midler | |
DK1296972T3 (da) | Arylmethylamin-derivater til anvendelse som tryptaseinhibitorer | |
HUP0102515A2 (hu) | Ciklopeptidek, eljárás előállításukra, hatóanyagként azokat tartalmazó gyógyszerkészítmények és alkalmazásuk | |
AR039190A1 (es) | Derivados de benzofurano, composicion farmaceutica y medicamento que comprende el compuesto | |
NO20022589L (no) | Anti-picornavirus-forbindelser og -preparater, deres farmasöytiske anvendelse og materialer for syntese av dem | |
NO20054346L (no) | Sammensetninger og fremgangsmater for forebygging og behandling av endotoksinrelaterte sykdommer og tilstander | |
NO20055749L (no) | Sulfamat benzotiofenderivater som steroid sulfatase inhibitorer |